ChemoCentryx plunges following split vote on avacopan approval from FDA committee Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- iBio (IBIO) up 34% after announcing the studies of BIO-202, being designed for the prevention of SARS-CoV-2 infections, identified no adverse effects at low or high doses
- Tilray (TLRY) up 6% after Jefferies analyst Owen Bennett double upgraded shares to Buy from Underperform with a $23 price target after resuming coverage of the name
UP AFTER EARNINGS -
- DraftKings (DKNG) up 4%
- Nikola (NKLA) up 5%
- Roku (ROKU) up 11%
- Peloton (PTON) up 5%
DOWN AFTER EARNINGS -
- Monster Beverage (MNST) down 5%
- Beyond Meat (BYND) down 8%
- Shake Shack (SHAK) down 10%
LOWER -
- PureCycle (PCT) down 7% after commenting on a short selling report from Hindenburg Research which called the company a "zero-revenue ESG SPAC charade"
- ChemoCentryx (CCXI) down 56% after announcing the split vote outcome of the FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody associated vasculitis
Symbols:
IBIO TLRY DKNG NKLA ROKU - $283.70 /
-20.23 (-6.66%)
PTON MNST BYND - $119.12 /
-2.455 (-2.02%)
SHAK PCT CCXI Keywords: Fly Intel, Wall Street, Top Stories, Stocks